NewEdge Advisors’s Annovis Bio ANVS Stock Holding History

NewEdge Advisors’s Portfolio ANVS Stock Details ANVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,500	Closed	-$70.9K	–	4141
2025 Q4	$70.9K	Buy	+20,500	New	+$61.6K	﹤0.01%	2861

Other funds holding ANVS

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

NewEdge Advisors's ANVS Position: Q1 2026 in Review

NewEdge Advisors sold out of Annovis Bio (ANVS) in Q1 2026, closing a stake of 20,500 shares — an estimated $70.9K sold.

NewEdge Advisors first reported a position in ANVS in Q4 2025 and held it in 1 quarter. The position peaked at $70.9K in Q4 2025. 56 funds tracked by Wall St. Rank hold ANVS as of Q1 2026.

NewEdge Advisors reported no remaining Annovis Bio position as of Q1 2026 after selling out during the quarter.
NewEdge Advisors sold 20,500 Annovis Bio shares in Q1 2026, an estimated $70.9K.
NewEdge Advisors first reported a position in Annovis Bio in Q4 2025 and held it in 1 quarter.
NewEdge Advisors's Annovis Bio position peaked at $70.9K in Q4 2025.
56 funds tracked by Wall St. Rank held Annovis Bio as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.